Gastroesophageal Reflux Disease in Children with Interstitial Lung Disease

Dziekiewicz, Marcin; Karolewska-Bochenek, Katarzyna; Dembiński, Łukasz; Gawrońska, Agnieszka; Krenke, Katarzyna; Lange, Joanna; Banasiuk, Marcin; Kuchar, Ernest; Kulus, Marek; Albrecht, Piotr; Banaszkiewicz, Aleksandra

doi:10.1007/5584_2016_229

Cited by 5 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gastroesophageal reflux disease (GERD), a common comorbidity in adult ILD patients, has been investigated also in chILD. In a study by Dziekiewicz and colleagues, the prevalence of GERD among children with ILD ( n = 18) aged 0.2–11.6 years was 50% [ 66 ].…”

Section: Non-pharmacological Treatmentsmentioning

confidence: 99%

Emerging Treatments for Childhood Interstitial Lung Disease

Bernardinello,

Griese,

Borie

et al. 2023

Pediatr Drugs

View full text Add to dashboard Cite

Childhood interstitial lung disease (chILD) is a large and heterogeneous group of disorders characterized by diffuse lung parenchymal markings on chest imaging and clinical signs such as dyspnea and hypoxemia from functional impairment. While some children already present in the neonatal period with interstitial lung disease (ILD), others develop ILD during their childhood and adolescence. A timely and accurate diagnosis is essential to gauge treatment and improve prognosis. Supportive care can reduce symptoms and positively influence patients' quality of life; however, there is no cure for many of the chILDs. Current therapeutic options include anti-inflammatory or immunosuppressive drugs. Due to the rarity of the conditions and paucity of research in this field, most treatments are empirical and based on case series, and less than a handful of small, randomized trials have been conducted thus far. A trial on hydroxychloroquine yielded good safety but a much smaller effect size than anticipated. A trial in fibrotic disease with the multitargeted tyrosine kinase inhibitor nintedanib showed similar pharmacokinetics and safety as in adults. The unmet need for the treatment of chILDs remains high. This article summarizes current treatments and explores potential therapeutic options for patients suffering from chILD.

show abstract

Section: Non-pharmacological Treatmentsmentioning

confidence: 99%

Emerging Treatments for Childhood Interstitial Lung Disease

Bernardinello,

Griese,

Borie

et al. 2023

Pediatr Drugs

View full text Add to dashboard Cite

show abstract

The link between airway reflux and non-acid reflux in children: a review

Saniasiaya

Kulasegarah

2023

Brazilian Journal of Otorhinolaryngology

View full text Add to dashboard Cite

Interstitial lung diseases in children

et al. 2020

View full text Add to dashboard Cite

Interstitial lung disease (ILD) in infants and children comprises a large spectrum of rare respiratory disorders that are mostly chronic and associated with high morbidity and mortality. These disorders are characterized by inflammatory and fibrotic changes that affect alveolar walls. Typical features of ILD include dyspnea, diffuse infiltrates on chest radiographs, and abnormal pulmonary function tests with restrictive ventilatory defect and/or impaired gas exchange. Many pathological situations can impair gas exchange and, therefore, may contribute to progressive lung damage and ILD. Consequently, diagnosis approach needs to be structured with a clinical evaluation requiring a careful history paying attention to exposures and systemic diseases. Several classifications for ILD have been proposed but none is entirely satisfactory especially in children. The present article reviews current concepts of pathophysiological mechanisms, etiology and diagnostic approaches, as well as therapeutic strategies. The following diagnostic grouping is used to discuss the various causes of pediatric ILD: 1) exposure-related ILD; 2) systemic disease-associated ILD; 3) alveolar structure disorder-associated ILD; and 4) ILD specific to infancy. Therapeutic options include mainly anti-inflammatory, immunosuppressive, and/or anti-fibrotic drugs. The outcome is highly variable with a mortality rate around 15%. An overall favorable response to corticosteroid therapy is observed in around 50% of cases, often associated with sequelae such as limited exercise tolerance or the need for long-term oxygen therapy.

show abstract

Gastroesophageal Reflux Disease in Children with Interstitial Lung Disease

Cited by 5 publications

References 29 publications

Emerging Treatments for Childhood Interstitial Lung Disease

Emerging Treatments for Childhood Interstitial Lung Disease

The link between airway reflux and non-acid reflux in children: a review

Interstitial lung diseases in children

Contact Info

Product

Resources

About